Category - Developments

Developments

Sigyn outlines 2023 achievements, 2024 outlook

In a letter to shareholders to Sigyn Therapeutics’ (OTCQB:SIGY) shareholders, Jim Joyce, chairman and CEO, said as a small organization operating in a world with short-term expectations, the company has “not wavered...

January 8, 2024

Developments

IntelGenx enters VetaFilm development license agreements under new animal health partnership

IntelGenx (TSX:IGX; OTCQB:IGXT) entered into development and license agreements with a wholly owned subsidiary of Covenant Animal Health Partners, who will fund the development and manufacturing of a VetaFilm-based drug...

December 18, 2023

Developments Markets

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Hepion Pharmaceuticals (NASDAQ:HEPA) announced a restructuring that, among other things, will suspend the enrollment of new patients in the Phase 2b ‘ASCEND-NASH’ clinical trial of its lead drug candidate, rencofilstat...

December 7, 2023

Developments

Anixa reports positive new data from Phase 1 breast cancer vaccine trial

Anixa Biosciences (NASDAQ:ANIX) and its partner, Cleveland Clinic, presented positive new results from the Phase 1 clinical trial of Anixa’s breast cancer vaccine at the 2023 San Antonio Breast Cancer Symposium (SABCS)...

December 7, 2023

Developments

Anixa reports European patent for ovarian cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) reported that its partner, Cleveland Clinic, received an intention-to-grant notice from the European Patent Office (EPO) for the patent application covering the company’s ovarian cancer...

November 27, 2023

Developments

SHINE Technologies, Nucleus RadioPharma in long-term supply pact

SHINE Technologies and Nucleus RadioPharma entered a multi-year supply agreement for lutetium-177, a radiopharmaceutical that is used for targeted cancer treatment. Nucleus, a contract development and manufacturing...

November 17, 2023

Developments

PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine

PharmaJet launched a Phase 1 clinical study evaluating a Venezuelan Equine Encephalitis (VEE) DNA vaccine delivered via the company’s needle-free Precision Delivery Systems. The Phase 1 trial, sponsored by PharmaJet and...

November 17, 2023

Developments

Firefly, WaveDancer in merger agreement

Closely-held Firefly Neuroscience and WaveDancer (NASDAQ:WAVD) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop...

November 16, 2023

Developments

LENZ Therapeutics, Graphite Bio in merger accord

Closely-held LENZ Therapeutics and Graphite Bio (NASDAQ:GRPH) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company, which will focus on advancing LENZ’...

November 15, 2023

Developments

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

IntelGenx (TSX:IGX; OTCQB:IGXT) reported that the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre approved the company’s planned clinical study to investigate the...

November 14, 2023

Category - Developments

Sigyn outlines 2023 achievements, 2024 outlook

IntelGenx enters VetaFilm development license agreements under new animal health partnership

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Anixa reports positive new data from Phase 1 breast cancer vaccine trial

Anixa reports European patent for ovarian cancer vaccine technology

SHINE Technologies, Nucleus RadioPharma in long-term supply pact

PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine

Firefly, WaveDancer in merger agreement

LENZ Therapeutics, Graphite Bio in merger accord

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

General

More